
£4 million funding raised for rapid vaccine development platform
Imophoron, the Bristol-based developer of a rapid-response vaccine platform, ADDomer, has secured £4 million in an oversubscribed fundraising round. Frederic Garzoni, CEO and Co-founder of Imophoron, said: “It has now been demonstrated how a pandemic cannot just threaten lives, but our society and economy as we know it. Imophoron is developing its ADDomer vaccine platform… Read More















